Table 3.

Relations of glucagon with NAFLD fibrotic progression in diabetic patients

	Glucagon, pg/mL					1SD increment of ln(glucagon)
	Quartile 1 (≤115.31)	Quartile 2 (115.32–154.12)	Quartile 3 (154.13–201.99)	Quartile 4 (>202)	P for trend
Indeterminate group	Reference	1.04 (0.69,1.57)	1.50 (0.97,2.31)	1.13 (0.76,1.70)	0.298	1.15 (0.87,1.51)
Presence of significant fibrosis	Reference	0.78 (0.46,1.33)	1.19 (0.69,2.06)	0.97 (0.57,1.64)	0.751	1.04 (0.72,1.50)
Fibrotic progression of NAFLD	Reference	0.87 (0.65,1.15)	1.03 (0.78,1.37)	0.96 (0.73,1.27)	0.889	1.00 (0.82,1.22)

Data are shown as regression odds ratios (95% CI). Multinomial and ordinal logistic regression analyses were used. Fibrotic progression of NAFLD: from absence of significant fibrosis, indeterminate results (NFS between −1.455 and 0.676) to presence of significant fibrosis (NFS >0.676). The model was adjusted for age, sex, duration of diabetes, current smoking, waist circumference, C-peptide, HbA1c, dyslipidemia, hypertension and use of incretins and SGLT2 inhibitors.